Isoquinoline compounds and uses thereof

US12378249B2 · kind B2 · utility

Assignee

• Genentech, Inc. · US

Inventors

• Jun Liang · Los Altos Hills, US
• Sushant Malhotra · South San Francisco, US
• Rohan Mendonca · South San Francisco, US
• Naomi Rajapaksa · San Mateo, US
• Michael Siu · Burlingame, US
• Craig Stivala · San Mateo, US
• John Tellis · San Mateo, US
• BinQing Wei · Belmont, US
• Bryan Chan · South San Francisco, US
• Joy Drobnick · South San Francisco, US
• Lewis Gazzard · Belmont, US
• Timothy Heffron · Burlingame, US
• Graham Elgin Jones · Harlow, GB
• Michael Lainchbury · Harlow, GB
• Andrew Madin · Hertford, GB
• Eileen Mary Seward · Bishop's Stortford, GB
• Matthew W. Cartwright · Harlow, GB
• Emanuela Gancia · Harlow, GB
• David Favor · Shanghai, CN
• Kin Chiu Fong · Shanghai, CN
• Andrew C. Good · Wallingford, US
• Yonghan Hu · Shanghai, CN

Key dates

• Filing date: Jan 22, 2021
• Grant date: Aug 5, 2025
• Expiry date: Jun 7, 2044

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D519/00
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

Isoquinoline compounds of formula (I): variations thereof, and their use as inhibitors of HPK1 (hematopoietic kinase 1) are described. The compounds are useful in treating HPK1-dependent disorders and enhancing an immune response. Also described are methods of inhibiting HPK1, methods of treating HPK1-dependent disorders, methods for enhancing an immune response, and methods for preparing the isoquinoline compounds.